C CARBONNEUTRAL (01372) announced its interim results, with a net profit attributable to owners of the company of 25.67 million Hong Kong dollars, turning a loss into a profit year-on-year.
China Carbon Neutral Limited (01372) announced its interim results for the six months ended on December 31, 2025. The revenue was approximately HK$352 million, representing a year-on-year growth of 14.4%. The net profit attributable to owners of the company was HK$25.667 million, turning around from a loss to a profit year-on-year. Earnings per share were HK$0.04.
C CARBONNEUTRAL (01372) announced its interim performance for the six-month period ending December 31, 2025, with revenues of approximately HK$352 million, a year-on-year growth of 14.4%. The company's attributable profit amounted to HK$25.67 million, turning from a loss to a profit; earnings per share were 4 HK cents.
The announcement stated that the turnaround to profit was mainly due to a fair value gain of approximately HK$49.3 million on carbon credit assets during the period and a reduction of approximately HK$12.7 million in estimated interest on convertible bonds, partially offset by an increase of approximately HK$2.7 million in employee benefits expenses.
Related Articles

G CHINA FIN (00431) intends to sell and Feng Limited.

US Stock Market Move | Performance outlook for 2026 falls short of expectations, Duolingo (DUOL.US) plunges over 26% in pre-market trading.

HENLIUS (02696): The phase II / III clinical study of HLX22 combined with HLX87 for first-line treatment of HER2-positive recurrent or metastatic breast cancer (BC) patients has completed the first patient dosing in China.
G CHINA FIN (00431) intends to sell and Feng Limited.

US Stock Market Move | Performance outlook for 2026 falls short of expectations, Duolingo (DUOL.US) plunges over 26% in pre-market trading.

HENLIUS (02696): The phase II / III clinical study of HLX22 combined with HLX87 for first-line treatment of HER2-positive recurrent or metastatic breast cancer (BC) patients has completed the first patient dosing in China.

RECOMMEND

Robot Concept Hong Kong Stocks Retreat After Spring Gala Rally As 2026 Emerges As Pivotal Year For Mass Production And Commercialization
25/02/2026

Hong Kong IPO Fundraising Surges Tenfold At Start Of Year As 110 A‑Share Companies Queue For Listings
25/02/2026

AI Iteration Risks Surface As Hong Kong Market Diverges; Low‑Valuation, High‑Dividend Legacy Stocks Attract Capital As Safe Havens
25/02/2026


